GlassScriptPhysician profile
Morgan Manulik
NPI 1124271960
$57,630.68
in general payments reported to CMS, 2019-2025
44 companies · $5,960 in 2025
The $5,960 reported for 2025 was more than what 99% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $20K · 2022: $15K · 2023: $9,280 · 2024: $7,238 · 2025: $5,960.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $21K · Food and Beverage: $1,716 · Consulting Fee: $150.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $20,612.50 |
| Food and Beverage | $1,716.04 |
| Consulting Fee | $150.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $46,970.70 | 2021-2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $3,926.89 | 2022 | |
| Allergan, INC. | $1,795.47 | 2021-2022 | |
| Biohaven Pharmaceuticals, INC. | $1,512.74 | 2021 | |
| Inspire Medical Systems, INC. | $914.09 | 2021-2025 | Inspire |
| Teva Pharmaceuticals USA, INC. | $535.13 | 2021-2023 | Austedo |
| Lilly USA, LLC | $237.39 | 2021-2025 | Zepbound, Emgality, Reyvow |
| Biogen, INC. | $209.20 | 2021-2023 | Tysabri |
| Sk Life Science, INC. | $150.41 | 2021-2023 | |
| Genzyme Corporation | $135.38 | 2021-2025 | |
| Optinose US, INC. | $122.38 | 2025 | |
| Novartis Pharmaceuticals Corporation | $110.91 | 2021-2022 | |
| Glaxosmithkline, LLC. | $94.87 | 2025 | Nucala |
| Jazz Pharmaceuticals INC. | $70.00 | 2022 | |
| Amgen INC. | $68.92 | 2022-2023 | Aimovig |
Show all 44 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Morgan Manulik listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.